Mind Medicine Analyst Ratings
Mind Medicine Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/23/2023 | 159.26% | RBC Capital | → $7 | Reiterates | Outperform → Outperform |
| 08/22/2023 | 159.26% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/04/2023 | 2677.78% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 08/04/2023 | 159.26% | RBC Capital | $5 → $7 | Maintains | Outperform |
| 08/04/2023 | 677.78% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 07/10/2023 | 85.19% | RBC Capital | → $5 | Reiterates | Outperform → Outperform |
| 06/28/2023 | 2677.78% | HC Wainwright & Co. | $75 → $75 | Reiterates | Buy → Buy |
| 06/21/2023 | 85.19% | RBC Capital | → $5 | Reiterates | Outperform → Outperform |
| 06/20/2023 | 677.78% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 05/18/2023 | 159.26% | Cantor Fitzgerald | → $7 | Reiterates | → Overweight |
| 05/18/2023 | 677.78% | EF Hutton | → $21 | Reiterates | Buy → Buy |
| 05/09/2023 | 2677.78% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 05/05/2023 | 677.78% | EF Hutton | → $21 | Reiterates | → Buy |
| 04/18/2023 | 2677.78% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 04/14/2023 | 714.81% | Oppenheimer | → $22 | Reiterates | → Outperform |
| 04/14/2023 | 677.78% | EF Hutton | → $21 | Reiterates | → Buy |
| 03/16/2023 | 2677.78% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 03/10/2023 | 85.19% | RBC Capital | → $5 | Reiterates | → Outperform |
| 03/10/2023 | 677.78% | EF Hutton | → $21 | Reiterates | → Buy |
| 01/19/2023 | 2677.78% | HC Wainwright & Co. | → $75 | Reiterates | → Buy |
| 12/16/2022 | 677.78% | EF Hutton | → $21 | Initiates Coverage On | → Buy |
| 11/16/2022 | 85.19% | RBC Capital | → $5 | Initiates Coverage On | → Outperform |
| 09/21/2022 | 2677.78% | HC Wainwright & Co. | $5 → $75 | Maintains | Buy |
| 08/26/2022 | 29.63% | Oppenheimer | → $3.5 | Initiates Coverage On | → Outperform |
| 08/16/2022 | 85.19% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 05/04/2022 | 159.26% | Roth Capital | → $7 | Initiates Coverage On | → Buy |
| 08/05/2021 | 270.37% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 06/28/2021 | 122.22% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/23/2023 | 159.26% | 加拿大皇家银行资本 | →$7 | 重申 | 跑赢→跑赢大盘 |
| 2023年08月22日 | 159.26% | 康托·菲茨杰拉德 | →$7 | 重申 | 超重→超重 |
| 08/04/2023 | 2677.78% | HC Wainwright公司 | →$75 | 重申 | →购买 |
| 08/04/2023 | 159.26% | 加拿大皇家银行资本 | $5→$7 | 维护 | 跑赢大盘 |
| 08/04/2023 | 677.78% | EF Hutton | →$21 | 重申 | 购买→购买 |
| 07/10/2023 | 85.19% | 加拿大皇家银行资本 | →$5 | 重申 | 跑赢→跑赢大盘 |
| 2023年6月28日 | 2677.78% | HC Wainwright公司 | $75→$75 | 重申 | 购买→购买 |
| 2023年6月21日 | 85.19% | 加拿大皇家银行资本 | →$5 | 重申 | 跑赢→跑赢大盘 |
| 06/20/2023 | 677.78% | EF Hutton | →$21 | 重申 | 购买→购买 |
| 2023年05月18日 | 159.26% | 康托·菲茨杰拉德 | →$7 | 重申 | →超重 |
| 2023年05月18日 | 677.78% | EF Hutton | →$21 | 重申 | 购买→购买 |
| 05/09/2023 | 2677.78% | HC Wainwright公司 | →$75 | 重申 | →购买 |
| 05/05/2023 | 677.78% | EF Hutton | →$21 | 重申 | →购买 |
| 04/18/2023 | 2677.78% | HC Wainwright公司 | →$75 | 重申 | →购买 |
| 04/14/2023 | 714.81% | 奥本海默 | →$22 | 重申 | →跑赢大盘 |
| 04/14/2023 | 677.78% | EF Hutton | →$21 | 重申 | →购买 |
| 03/16/2023 | 2677.78% | HC Wainwright公司 | →$75 | 重申 | →购买 |
| 03/10/2023 | 85.19% | 加拿大皇家银行资本 | →$5 | 重申 | →跑赢大盘 |
| 03/10/2023 | 677.78% | EF Hutton | →$21 | 重申 | →购买 |
| 2023年1月19日 | 2677.78% | HC Wainwright公司 | →$75 | 重申 | →购买 |
| 12/16/2022 | 677.78% | EF Hutton | →$21 | 开始承保 | →购买 |
| 2022年11月16日 | 85.19% | 加拿大皇家银行资本 | →$5 | 开始承保 | →跑赢大盘 |
| 2022/09/21 | 2677.78% | HC Wainwright公司 | $5→$75 | 维护 | 买 |
| 2022年08月26日 | 29.63% | 奥本海默 | →$3.5 | 开始承保 | →跑赢大盘 |
| 08/16/2022 | 85.19% | HC Wainwright公司 | $10→$5 | 维护 | 买 |
| 05/04/2022 | 159.26% | 罗斯资本 | →$7 | 开始承保 | →购买 |
| 08/05/2021 | 270.37% | HC Wainwright公司 | →$10 | 开始承保 | →购买 |
| 2021/06/28 | 122.22% | Maxim集团 | →$6 | 开始承保 | →购买 |
What is the target price for Mind Medicine (MNMD)?
精神药物(MNMD)的目标价格是多少？
The latest price target for Mind Medicine (NASDAQ: MNMD) was reported by RBC Capital on October 23, 2023. The analyst firm set a price target for $7.00 expecting MNMD to rise to within 12 months (a possible 159.26% upside). 22 analyst firms have reported ratings in the last year.
精神药物(纳斯达克：MNMD)的最新目标价是由加拿大皇家银行资本于2023年10月23日报道的。这家分析公司将目标价定为7美元，预计MNMD将在12个月内升至(可能上涨159.26%)。过去一年，有22家分析公司公布了评级。
What is the most recent analyst rating for Mind Medicine (MNMD)?
精神医学(MNMD)的最新分析师评级是多少？
The latest analyst rating for Mind Medicine (NASDAQ: MNMD) was provided by RBC Capital, and Mind Medicine reiterated their outperform rating.
纳斯达克(Sequoia Capital：MNMD)的最新分析师评级由加拿大皇家银行资本提供，Mind Medicine重申其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Mind Medicine (MNMD)?
Mind Medicine(MNMD)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mind Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mind Medicine was filed on October 23, 2023 so you should expect the next rating to be made available sometime around October 23, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Mind Medicine的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。精神医学的上一次评级是在2023年10月23日提交的，所以你应该预计下一次评级将在2024年10月23日左右提供。
Is the Analyst Rating Mind Medicine (MNMD) correct?
分析师对精神医学(MNMD)的评级正确吗？
While ratings are subjective and will change, the latest Mind Medicine (MNMD) rating was a reiterated with a price target of $0.00 to $7.00. The current price Mind Medicine (MNMD) is trading at is $2.70, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的精神医学(MNMD)评级被重申，目标价在0.00美元到7.00美元之间。Mind Medicine(MNMD)目前的交易价格为2.70美元，在分析师的预测范围内。